Breakthroughs in Targeted Therapies Not Applicable if Not Cost-Effective

Marie Rosenthal, MS
Published: Friday, Apr 20, 2012
Image of stethoscope, pills, and 20 dollar billsBefore the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers that determine which therapies patients should receive.


1. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012; 106(6):1100- 1106. doi:10.1038/bjc.2012.60.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication